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We are grateful for Dr. Lockhart’s interest and close reading of our article proposing an 
approach for identifying severe maternal morbidity in birthing facilities.1 Dr. Lockhart raises 
an important point regarding transfusion of blood products, and we agree that this point 
requires clarification. The use of the term “blood products” could be confusing, especially 
when considering pooled blood components.
We would like to use this opportunity to clarify that for the purpose of facility-based review, 
“severe maternal morbidity” should be defined as women who are admitted to an intensive 
care unit, women who receive 4 or more units of blood (packed red blood cells or whole 
blood), or both. This definition will identify essentially the same women as would have been 
identified if other blood products also were included, but it would avoid potential confusion. 
For example, based on data used by You et al2 in their study of severe maternal morbidity, 
nearly all women who would have been identified as having had severe morbidity only 
because they received blood products other than packed cells or whole blood would have 
been identified anyway because they were admitted to an intensive care unit.
Identification and review of severe maternal morbidity is an evolving process, and we 
acknowledge that institutions may elect to include criteria in addition to intensive care unit 
admission, transfusion of 4 or more units of blood, or both. We look forward to participating 
in ongoing discussions about review of severe maternal morbidity as a key component of 
quality improvement for maternity care, and we thank Dr. Lockhart for her insight regarding 
a potential point of confusion.
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